QR-Code

Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

Abstract Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with ide-cel in patients with extramedullary disease (EMD) remain incompletely characterized. We included patients w...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Saurabh Zanwar, Surbhi Sidana, Leyla Shune, Omar Castaneda Puglianini, Oren Pasvolsky, Rebecca Gonzalez, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, James A. Davis, Megan Herr, Hamza Hashmi, Peter Forsberg, Douglas Sborov, Larry D. Anderson Jr, Joseph P. McGuirk, Charlotte Wagner, Alex Lieberman-Cribbin, Adriana Rossi, Ciara L. Freeman, Frederick L. Locke, Shambavi Richard, Jack Khouri, Yi Lin, Krina K. Patel, Shaji K. Kumar, Doris K. Hansen
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMC 2024-06-01
Schriftenreihe:Journal of Hematology & Oncology
Schlagworte:
BCMA CAR-T
Ide-cel
Relapsed/refractory myeloma
Radiation
Immunotherapy
Online-Zugang:https://doi.org/10.1186/s13045-024-01555-4
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge